Immutep

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Immutep and other ETFs, options, and stocks.

About IMMP

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731).

CEO

Marc Voigt

CEOMarc Voigt

Employees

—

Employees—

Headquarters

Sydney, New South Wales (NSW)

HeadquartersSydney, New South Wales (NSW)

Founded

1987

Founded1987

Employees

—

Employees—

IMMP Key Statistics

Market cap

238.77M

Market cap238.77M

Price-Earnings ratio

-7.47

Price-Earnings ratio-7.47

Dividend yield

—

Dividend yield—

Average volume

64.46K

Average volume64.46K

High today

$1.69

High today$1.69

Low today

$1.63

Low today$1.63

Open price

$1.69

Open price$1.69

Volume

58.38K

Volume58.38K

52 Week high

$2.72

52 Week high$2.72

52 Week low

$1.32

52 Week low$1.32

Analyst ratings

100%

of 7 ratings

Buy

100%

Hold

Sell

Immutep

Why Robinhood?

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). Show more

IMMP Key Statistics

Analyst ratings

100%

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731).